Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294723 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 746
- Enrollment target
NCT00294723 is a Phase 3 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 746 participants.
The verdict
NCT00294723, a Phase 3 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 746 participants
- Enrollment target
Study Summary
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 746 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294723
The ClinicalTrials.gov registry entry for NCT00294723 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 746 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00294723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294723 about?
NCT00294723 is a clinical study titled "To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c". This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open...
What is the current status of trial NCT00294723?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 746 participants. The study started on 2006-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00294723?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), glimepiride (DRUG).
Who is sponsoring clinical trial NCT00294723?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.